Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market? [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
drugs, with Lilly's share price more than quadrupling and Novo's shares more than tripling over the last three years. Meanwhile, Pfizer 's (NYSE: PFE) fortunes have taken a different path. The big pharma stock has plunged with sinking sales of its COVID-19 products. But can Pfizer possibly challenge Lilly and Novo Nordisk in the obesity market? Murky outlook Pfizer had high hopes for danuglipron, a GLP-1 agonist like Novo Nordisk's Ozempic and Wegovy. However, those hopes suffered a severe blow after the company announced the results from a phase 2 study of a twice-daily oral formulation of the drug. The side effects were so bad that Pfizer opted not to advance the twice-daily danuglipron into late-stage testing. But Pfizer didn't throw in the towel on the program. The drugmaker still has a phase 1 study evaluating a once-daily formulation of danuglipron. It's fair to say that Wall Street is skeptical about the prospects for the drug, though. During Pfizer's recent first-quart
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Moderna wins patent case in Europe against Pfizer, BioNTech over COVID shot [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Pfizer Stock: Rebound Has Started (Technical Analysis) [Seeking Alpha]Seeking Alpha
- Active Pharmaceutical Ingredient Market Worth $238.3 billion | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield [Seeking Alpha]Seeking Alpha
- 2 Top Growth Stocks Down 24% and 50% to Buy With $100 [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 5/16/24 - Form 4
- 5/16/24 - Form 4
- 5/9/24 - Form S-8
- PFE's page on the SEC website